Sugi Predict

Sugi Predict / Compounds / SCHEMBL391910

SCHEMBL391910

SCHEMBL391910

CON=C(c1ccc(Cl)cc1)C1CC1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.56
▸ CCR5 P51681 4/20 0.44
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ DRD4 P21917 5/20 0.38
▸ DRD2 P14416 2/20 0.38
▸ MGLL Q99685 1/20 0.38
▸ HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18574082 1.00 CYP1A2 (0.56) CYP1A2CCR5KMT2AMEN1ALDH1A1
SCHEMBL9189394 0.81 MEN1 (0.41) CYP1A2CCR5KMT2AMEN1
SCHEMBL11057264 0.77 CYP1A2 (0.62) CYP1A2KMT2AMEN1MGLL
SCHEMBL11048179 0.77 CYP1A2 (0.62) CYP1A2KMT2AMEN1MGLL
SCHEMBL10811484 0.77 CYP1A2 (0.62) CYP1A2KMT2AMEN1MGLL
SCHEMBL20686597 0.76 CCR5 (0.40) CCR5ALDH1A1CYP2D6DRD4DRD2
SCHEMBL25890252 0.75 RAB9A (0.56) KMT2AMEN1ALDH1A1HPGD
SCHEMBL25890258 0.75 RAB9A (0.56) KMT2AMEN1ALDH1A1HPGD
SCHEMBL25890294 0.75 RAB9A (0.43) CYP1A2CCR5
SCHEMBL25890263 0.74 POLB (0.42) CCR5KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-10654855-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2020-05-19 — — US disclosed
US-20180312516-A1 Protein Kinase B Inhibitors ASTRAZENECA AB (SE) 2018-11-01 — — US disclosed
US-10059714-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2018-08-28 — — US disclosed
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2017-03-02 — — US disclosed
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2015-07-02 — — US disclosed
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2015-07-02 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
EP-2201012-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS AstraZeneca AB (SE) 2010-06-30 — — EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CCR5 2073/4885KMT2A 1343/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CCR5 2073/4885KMT2A 1343/4885
US-20180312516-A1 Protein Kinase B Inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CCR5 2073/4885KMT2A 1343/4885
US-10654855-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CCR5 2073/4885KMT2A 1343/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CCR5 2073/4885KMT2A 1343/4885
US-10059714-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CCR5 2073/4885KMT2A 1343/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP1A2 3895/4885CCR5 2018/4885KMT2A 1599/4885
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP1A2 3895/4885CCR5 2018/4885KMT2A 1599/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CCR5 2073/4885KMT2A 1343/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP1A2 3895/4885CCR5 2018/4885KMT2A 1599/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CCR5 2073/4885KMT2A 1343/4885
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP1A2 3895/4885CCR5 2018/4885KMT2A 1599/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CCR5 2073/4885KMT2A 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.